This trial is unknown!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Breast Cancer
and you are
over 18
years old
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

The purpose of this study is to determine the efficacy of the combined therapy Bevacizumab, trastuzumab and paclitaxel in neo-adjuvant therapy in patients with breast cancer HER 2+ followed by surgery and adjuvant therapy (Cyclophosphamide, Trastuzumab and Doxorubicin liposomal).

Provided treatments

  • Drug: Bevacizumab,Trastuzumab,Paclitaxel,Cyclophosphamide,Myocet

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01321775. The sponsor of the trial is Hospital Universitario Madrid Sanchinarro and it is looking for 44 volunteers for the current phase.
Official trial title:
Bevacizumab and Trastuzumab With Paclitaxel on Women With Her2+ Breast Cancer Weekly Paclitaxel Followed, After Surgery, by Encapsuled Liposomal Doxorubicin, Cyclophosphamide and Trastuzumab as Adjuvant Treatment After Surgery on Women With Her2+ Breast Cancer